- Revenues down by € 0.9 million to € 16.2 million
- EBIT of € 4.6 million, 28 % margin
- Earnings after taxes down by € 1.1 million to € 4.6 million
- Forecast for fiscal year 2021/2022
- Stable sales of € 16.0 million to € 16.5 million
- Stable EBIT of € 4.0 million to € 4.5 million.
Bremen, January 27, 2022 – MeVis Medical Solutions AG [ISIN: DE000A0LBFE4], a leading medical imaging software company, today announces its results for the fiscal year 2020/2021, with reporting period October 1, 2020 to September 30, 2021.
Revenues in the past fiscal year 2020/2021 amounted to € 16.2 million (compared with € 17.1 million in the fiscal year 2019/2020). Of this figure, 30% (previous year: 31%) was generated from license revenues of € 4.8 million (previous year: € 5.3 million), 34% (previous year: 36%) from maintenance contracts (software service contracts) of € 5.5 million (previous year: € 6.2 million), and 36% (previous year: 33%) from other revenues of € 5.8 million (previous year: € 5.6 million).
The year-on-year decline in revenue is mainly attributable to the expected decrease in license and maintenance revenue from the customer Hologic. In contrast, revenues from development services increased as more services were provided to the Varex Imaging Group.
The results continue to be satisfactory. Thus, EBIT (earnings before interest and taxes) of € 4.6 million was generated in 2020/2021, compared to € 5.8 million in 2019/2020. The EBIT margin deteriorated accordingly to 28% compared to the previous year's figure of 34%.
As a result of the fiscal unity, only minor income taxes of € 0.1 million were incurred in the past fiscal year, identical to the previous year.
This results in earnings after taxes of € 4.5 million (28% margin) for fiscal year 2020/2021, compared with € 5.7 million (33% margin) in 2019/2020. The profit of € 4,546 k will be transferred to Varex Imaging Deutschland AG on the basis of the control and profit transfer agreement.
For fiscal year 2021/2022, sales of € 16.0 million to € 16.5 million are now expected to remain stable compared to the previous year. In addition to the slight decline in sales with the customer Hologic, slightly increasing sales revenues are expected in the area of development services. For earnings before interest and taxes (EBIT), we also expect stability in the range of € 4.0 million to € 4.5 million. The forecast sales stability, with an expected break-even result from exchange rate differences, is the main driver for the unchanged outlook for EBIT. Possible impact of the current Corona pandemic has played a role in the budget preparation.
The half-year financial report for fiscal year 2021/2022 will be published on May 30, 2022.